guest ::
000798162 001__ 798162 000798162 005__ 20230215042535.0 000798162 0247_ $$2CORDIS$$aG:(EU-Grant)874586$$d874586 000798162 0247_ $$2CORDIS$$aG:(EU-Call)H2020-SC1-2019-Single-Stage-RTD$$dH2020-SC1-2019-Single-Stage-RTD 000798162 0247_ $$2originalID$$acorda__h2020::874586 000798162 035__ $$aG:(EU-Grant)874586 000798162 150__ $$aControlled Organoids transplantation as enabler for regenerative medicine translation$$y2020-01-01 - 2023-06-30 000798162 371__ $$aDWI LEIBNIZ-INSTITUT FUR INTERAKTIVE MATERIALIEN EV$$dGermany$$ehttp://www.dwi.rwth-aachen.de$$vCORDIS 000798162 371__ $$aKing's College London$$dUnited Kingdom$$ehttps://www.kcl.ac.uk/index.aspx$$vCORDIS 000798162 371__ $$aCSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE SA - RECHERCHE ET DEVELOPPEMENT$$bCSEM$$dSwitzerland$$ehttp://www.csem.ch$$vCORDIS 000798162 371__ $$aKUGELMEIERS AG$$dSwitzerland$$ehttp://www.kugelmeiers.com$$vCORDIS 000798162 371__ $$aREGENHU SA$$dSwitzerland$$ehttp://www.regenhu.com$$vCORDIS 000798162 371__ $$aAMIRES SRO$$dCzech Republic$$vCORDIS 000798162 371__ $$aUtrecht University$$bUtrecht University$$dNetherlands$$ehttp://www.uu.nl/en$$vCORDIS 000798162 371__ $$aVIB VZW$$bVLAAMS INSTITUUT BIOTECHNOLOGIE FLANDERS INSTITUTE FOR BIOTECHNOLOGY$$dBelgium$$ehttp://www.vib.be$$vCORDIS 000798162 372__ $$aH2020-SC1-2019-Single-Stage-RTD$$s2020-01-01$$t2023-06-30 000798162 450__ $$aORGANTRANS$$wd$$y2020-01-01 - 2023-06-30 000798162 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union 000798162 680__ $$aEnd-stage liver failure is a major healthcare challenge. Liver diseases account for approximately 2 million deaths per year worldwide. Liver transplantation is the most effective way to re-establish a liver with normal functions for various diseases including acute liver failure or liver malignancies. Currently, less than 10% of global transplantation needs are met and the gap between patients on transplant waiting lists and available donor organs is steadily increasing. ORGANTRANS proposes a disruptive alternative to donor organs for patients with chronic or end-stage liver diseases who have still to isolate autologous liver stem cells. Driven by a need of leading European transplant centers, ORGANTRANS will tackle current obstacles for liver regenerative medicine by combining advanced know-how in cell biology, biomaterials, bioengineering, automation, standardization and clinical translation. ORGANTRANS will develop a liver tissue printing platform that will be shortly deployed under the “compassionate use exemption” by three leading European transplant centers belonging to the consortium or the External Advisory Board. ORGANTRANS will not only deliver an ATMP, but also platform technologies that can be scaled to other organ systems, as organoid technology is one of the largest parts of regenerative medicine. The project covers the entire value chain (from cell source, tissue engineering, bioprinting, post-processing to testing) allowing for early adoption of its results (product & process) in clinical practice. The platform will first be scaled to Europe and then to the rest of the world. 000798162 909CO $$ooai:juser.fz-juelich.de:880609$$pauthority$$pauthority:GRANT 000798162 909CO $$ooai:juser.fz-juelich.de:880609 000798162 970__ $$aoai:dnet:corda__h2020::6c375bba05fd51f619aaf45202ca3470 000798162 980__ $$aG 000798162 980__ $$aCORDIS 000798162 980__ $$aAUTHORITY